 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ICM-203 / Yonsei Technology Holdings
Trial completion date, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - May 14, 2024
P1/2, N=16, Recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | ICM-203 / Yonsei Technology Holdings
Trial completion date: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - Aug 7, 2023
P1/2, N=16, Recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Trial completion date: Jun 2024 --> Dec 2024
- ICM-203 / Yonsei Technology Holdings
Safety and Biodistribution Study of Intra-Articular Delivered ICM-203, an AAV Gene Therapy Vector for Osteoarthritis, in Normal Rodents and Osteoarthritis-Induced Beagle Dogs (Petree Hall C) - May 3, 2023 - Abstract #ASGCT2023ASGCT_2406;
In addition, no abnormalities were found in terms of immunogenicity. Overall, these results were included in the ICM-203 IND submission and the program received no study hold comment from the US FDA in Oct 2022.
- ||| ICM-203 / Yonsei Technology Holdings
Enrollment open: A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo (clinicaltrials.gov) - Mar 28, 2023
P=N/A, N=16, Enrolling by invitation, Sponsor: ICM Co. Ltd.
Overall, these results were included in the ICM-203 IND submission and the program received no study hold comment from the US FDA in Oct 2022. Not yet recruiting --> Enrolling by invitation
- |||||| ICM-203 / Yonsei Technology Holdings
New trial: A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo (clinicaltrials.gov) - Mar 2, 2023
P=N/A, N=16, Not yet recruiting, Sponsor: ICM Co. Ltd.
- | ICM-203 / Yonsei Technology Holdings
Trial completion date, Trial initiation date, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (clinicaltrials.gov) - Nov 14, 2022
P1/2, N=18, Not yet recruiting, Sponsor: ICM Co. Ltd.
Not yet recruiting --> Enrolling by invitation Trial completion date: Dec 2024 --> May 2025 | Initiation date: Dec 2022 --> May 2023 | Trial primary completion date: Jun 2024 --> Nov 2024
- | ICM-203 / Yonsei Technology Holdings
Trial completion date, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (clinicaltrials.gov) - Sep 9, 2022
P1/2, N=24, Not yet recruiting, Sponsor: ICM Co. Ltd.
Trial completion date: Dec 2024 --> May 2025 | Initiation date: Dec 2022 --> May 2023 | Trial primary completion date: Jun 2024 --> Nov 2024 Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
- ||| ICM-203 / Yonsei Technology Holdings
Enrollment change, Trial completion date, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - Sep 9, 2022
P1/2, N=16, Recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Jun 2024 N=24 --> 16 | Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
- || ICM-203 / Yonsei Technology Holdings
New P1/2 trial: A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (clinicaltrials.gov) - Jul 12, 2022
P1/2, N=24, Not yet recruiting, Sponsor: ICM Co. Ltd.
- || ICM-203 / Yonsei Technology Holdings
Enrollment open: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - May 24, 2022
P1/2, N=24, Recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
N=24 --> 16 | Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Mar 2024 Not yet recruiting --> Recruiting
- | ICM-203 / Yonsei Technology Holdings
Trial completion date, Trial initiation date, Trial primary completion date: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - Jan 31, 2022
P1/2, N=24, Not yet recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
Not yet recruiting --> Recruiting Trial completion date: Jun 2023 --> Sep 2023 | Initiation date: Sep 2021 --> Feb 2022 | Trial primary completion date: Feb 2023 --> Jun 2023
- | ICM-203 / Yonsei Technology Holdings
Trial initiation date: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - Aug 24, 2021
P1/2, N=24, Not yet recruiting, Sponsor: ICM Biotech Australia Pty Ltd.
Trial completion date: Jun 2023 --> Sep 2023 | Initiation date: Sep 2021 --> Feb 2022 | Trial primary completion date: Feb 2023 --> Jun 2023 Initiation date: Jun 2021 --> Sep 2021
- | ICM-203 / Yonsei Technology Holdings
New P1/2 trial: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (clinicaltrials.gov) - May 5, 2021
P1/2, N=24, Not yet recruiting, Sponsor: ICM Biotech Australia Pty Ltd.